Noroxymorphone

Noroxymorphone
Clinical data
Routes of; administration	intravenous, intramusucular, subcutaneous, oral, rectal, intranasal
Legal status
Legal status	US: Schedule II;
Identifiers
	IUPAC name 7,8-Dihydro-14-hydroxynormorphinone;
CAS Number	33522-95-1;
PubChem CID	5497189;
DrugBank	DBMET00424;
ChemSpider	4593755;
UNII	9NZ7111A9O;
CompTox Dashboard (EPA)	DTXSID80955145 ;
ECHA InfoCard	100.046.859
Chemical and physical data
Formula	C16H17NO4
Molar mass	287.315 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Oc1ccc2C[C@H]3NCC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O;
	InChI InChI=1S/C16H17NO4/c18-9-2-1-8-7-11-16(20)4-3-10(19)14-15(16,5-6-17-11)12(8)13(9)21-14/h1-2,11,14,17-18,20H,3-7H2/t11-,14+,15+,16-/m1/s1; Key:HLMSIZPQBSYUNL-IPOQPSJVSA-N;

Noroxymorphone is an opioid^[1] which is both a metabolite of oxymorphone and oxycodone and is manufactured specifically as an intermediate in the production of narcotic antagonists such as naltrexone and others. It is a potent agonist of the μ-opioid receptor, but is poorly able to cross the blood-brain-barrier into the central nervous system, and for this reason, has only minimal analgesic activity.^[2]^[3]^[1]

In the United States, noroxymorphone is controlled as a Schedule II Narcotic controlled substance with an ACSCN of 9637 and in 2014 the DEA set annual aggregate manufacturing quotas of 17 500 kilogrammes for conversion and 1262.5 kg for sale.^[4] In other countries, it may be similarly controlled, controlled at a lower level, or regulated in another way.

References

1 2 Lemberg KK, Siiskonen AO, Kontinen VK, Yli-Kauhaluoma JT, Kalso EA (February 2008). "Pharmacological characterization of noroxymorphone as a new opioid for spinal analgesia". Anesthesia and Analgesia. 106 (2): 463–70, table of contents. doi:10.1213/ane.0b013e3181605a15. PMID 18227301. S2CID 16524280.
↑ Preedy VR (25 April 2016). Neuropathology of Drug Addictions and Substance Misuse Volume 3: General Processes and Mechanisms, Prescription Medications, Caffeine and Areca, Polydrug Misuse, Emerging Addictions and Non-Drug Addictions. Elsevier Science. pp. 462–464. ISBN 978-0-12-800677-1.
↑ Smith H, Passik S (25 April 2008). Pain and Chemical Dependency. Oxford University Press, USA. pp. 195–. ISBN 978-0-19-530055-0.
↑ Drug Enforcement Administration (August 25, 2014). "Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2014". Federal Register. Vol. 79, no. 164. pp. 50700–50704. Archived from the original on March 4, 2016. Retrieved February 27, 2016.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[Lemberg_2008-1] 1 2 Lemberg KK, Siiskonen AO, Kontinen VK, Yli-Kauhaluoma JT, Kalso EA (February 2008). "Pharmacological characterization of noroxymorphone as a new opioid for spinal analgesia". Anesthesia and Analgesia. 106 (2): 463–70, table of contents. doi:10.1213/ane.0b013e3181605a15. PMID 18227301. S2CID 16524280.

[Preedy2016-2] Preedy VR (25 April 2016). Neuropathology of Drug Addictions and Substance Misuse Volume 3: General Processes and Mechanisms, Prescription Medications, Caffeine and Areca, Polydrug Misuse, Emerging Addictions and Non-Drug Addictions. Elsevier Science. pp. 462–464. ISBN 978-0-12-800677-1.

[SmithPassik2008-3] Smith H, Passik S (25 April 2008). Pain and Chemical Dependency. Oxford University Press, USA. pp. 195–. ISBN 978-0-19-530055-0.

[4] Drug Enforcement Administration (August 25, 2014). "Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2014". Federal Register. Vol. 79, no. 164. pp. 50700–50704. Archived from the original on March 4, 2016. Retrieved February 27, 2016.

[1]

[2]

[3]

[4]

See also

References